Recarbrio(relebactam)
Recarbrio (relebactam) is a small molecule pharmaceutical. Relebactam was first approved as Recarbrio on 2019-07-16. It is used to treat intraabdominal infections, pyelonephritis, and urinary tract infections in the USA. It has been approved in Europe to treat gram-negative bacterial infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Combinations
Recarbrio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cilastatin sodium
+
Imipenem
+
Relebactam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RECARBRIO | Merck & Co | N-212819 RX | 2019-07-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| recarbrio | New Drug Application | 2023-07-26 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| intraabdominal infections | — | D059413 | — |
| pyelonephritis | EFO_1001141 | D011704 | N10-N16 |
| urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO | |||
| 2029-07-16 | GAIN | ||
| 2024-07-16 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co | |||
| 8487093 | 2029-11-19 | DS, DP | U-2586, U-2587, U-2840 |
HCPCS
Code | Description |
|---|---|
| J0742 | Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg |
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | 1 | 1 | — | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
| Gram-negative bacterial infections | D016905 | — | — | — | — | — | 1 | — | 1 |
| Critical illness | D016638 | — | — | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 1 | 1 | 2 | — | 1 | 4 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 2 | — | — | 2 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 1 | 1 | — | — | 2 |
| Intraabdominal infections | D059413 | — | — | — | 1 | 1 | — | — | 2 |
| Iatrogenic disease | D007049 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | HP_0100806 | A41.9 | 2 | — | — | — | — | 2 |
| Communicable diseases | D003141 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Relebactam |
| INN | relebactam |
| Description | Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio).
|
| Classification | Small molecule |
| Drug class | beta-lactamase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O.O=C(NC1CCNCC1)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 1174018-99-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301605 |
| ChEBI ID | — |
| PubChem CID | 44129647 |
| DrugBank | DB12377 |
| UNII ID | 1OQF7TT3PF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,630 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use